Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

Delayed Quote. Delayed  - 05/06 05:30:46 pm
17.1 CHF   -0.29%
04/28 NEWRON PHARMACE : Zambon Launches Xadago® (Safinamide) In Denmark An..
04/28 NEWRON PHARMACE : Zambon Launches Xadago® (Safinamide) in Denmark an..
04/11 NEWRON PHARMACE : and Partner Zambon Support Parkinson's Disease Awa..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20142015Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs1.58100%1.9279.1% +21.76%
Sales per Regions
20142015Delta
CHF (in Million)%CHF (in Million)%
Global1.58100%1.9279.1% +21.76%
Managers
NameAgeSinceTitle
Stefan Weber512005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD642013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD592005Chief Medical Officer
Patrick J. Langlois, PhD712008Independent Non-Executive Director
Robert Leslie Holland MD, PhD612013Independent Non-Executive Director
Bo Jesper Hansen MD, PhD582013Independent Non-Executive Director
Joseph Donald deBethizy, PhD652014Independent Non-Executive Director
Luca Benatti, PhD552014Independent Non-Executive Director
Marco Caremi592002Executive Vice President-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 14,432,911 10,228,033 70.9% 0 0.0% 70.9%
Shareholders
NameEquities%
Investor AB 1,772,817 12.3%
Gefim SpA 1,311,957 9.09%
JPMorgan Asset Management (UK) Ltd. 409,571 2.84%
Swisscanto Fondsleitung AG 351,386 2.43%
UBS AG (Investment Management) 228,945 1.59%
Polar Capital LLP 164,704 1.14%
Aviva Investors Global Services Ltd. 111,637 0.77%
Credit Suisse AG 94,199 0.65%
Michel & Cortesi Asset Management AG 48,218 0.33%
Zürcher Kantonalbank (Investment Management) 32,898 0.23%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
GILEAD SCIENCES, ..
AMGEN, INC.
CELGENE CORPORATI..
REGENERON PHARMAC..
VERTEX PHARMACEUT..
ACTELION LTD
MEDIVATION INC
GENMAB A/S
TONGHUA DONGBAO P..
HUALAN BIOLOGICAL..
JUNO THERAPEUTICS..
NEUROCRINE BIOSCI..
INTERCEPT PHARMAC..
PEPTIDREAM INC
CHINA BIOLOGIC PR..
BEIJING SL PHARMA..
ULTRAGENYX PHARMA..
ZHONGYUAN UNION C..
KITE PHARMA INC
ANHUI ANKE BIOTEC..
Sector Biotechnology & Medical Research
Newron Pharmaceuticals SpA : Connections
NOXXON Pharma AG
Early Clinical Development Consulting Ltd.
DFC Langlois
Assobiotec
Karolinska Development AB (Private Equity)
PJL Consulting
Italian Angels For Biotech
Constantia Flexibles AG
Oxford Gene Technology IP Ltd.
Constantia Flexibles Group GmbH
CMC Contrast AB
European School of Management & Technology GmbH
MipSalus ApS
EryDel SpA
Orphazyme ApS
Universitätsklinikum Würzburg
White City Consulting ApS
The European Association for Bioindustries
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
© 2016 People , Fundamentals and Ownership